

■ **The oral antiviral agent oseltamivir ['Tamiflu'; Roche] dominated the US 'flu market throughout the 2000/2001 influenza season, according to IMS prescription data reported in *Scrip*. Oseltamivir's market share rose from 87% of neuraminidase inhibitor prescriptions for the week ending 24 November 2000, climbing steadily to about 95% of neuraminidase inhibitor prescriptions in the week ending 23 February this year. Contributing to oseltamivir's advantage over its nearest market rival, the inhaled antiviral agent zanamivir ['Relenza'; GlaxoSmithKline] is the additional approval for 'flu prophylaxis in the US.**

Tamiflu beats Relenza in US prescription battle. *Scrip* : 21, No. 2630, 30 Mar 2001 800817567